ReviewFrontiers in medicine2017
Metabolic Disorders in Chronic Lung Diseases.
Review in Frontiers in medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 51 citations in OpenAlex.
- Metabolomics-guided Mechanisms of Mesenchymal Stromal Cell and Exosome Therapies in Chronic Diseases.Stem cell reviews and reports · 2026Review
- Multi-omics integration identifies associations between large high-density lipoprotein and lung function, asthma, and COPD: evidence from genetic and population-based analyses.Respiratory research · 2026Article
- High density lipoproteins, disease severity and clinical outcomes in patients with idiopathic pulmonary fibrosis.Respiratory research · 2026Article
- Triglyceride-glucose index and preserved ratio impaired spirometry in 89,809 individuals without self-reported overt clinical disease.Frontiers in medicine · 2026Article
- Relation Between Obesity, Normal-Weight Obesity, and Risk of Diabetes Among Youth and Females - A Systematic Review and Meta-Analysis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Artificial Intelligence with Robotics for Metabolic Rehabilitation and Enhanced Patient Recovery in Critical Care.Research (Washington, D.C.) · 2026Review
- The relationship between the triglyceride-glucose index and lung function in healthy individuals: a cross-sectional study of 89,809 participants from Kangbuk Samsung health study.BMC pulmonary medicine · 2025Observational
- The interactions among factors associated with the risk of lung cancer among diabetes patients: a survival tree analysis.NPJ primary care respiratory medicine · 2025Article
- Association between body roundness index and weight-adjusted waist index with asthma prevalence among US adults: the NHANES cross-sectional study, 2005-2018.Scientific reports · 2025Article
- Are patients with chronic obstructive pulmonary disease at a greater risk for the development of autoimmune thyroiditis as an adverse event of immunotherapy in non-small cell lung cancer treatment?Pathology oncology research : POR · 2025Observational
- Triglyceride-glucose index as an independent predictor of mortality in patients with chronic respiratory diseases.Frontiers in pharmacology · 2025Article
- Macrophage Immunometabolism in Pulmonary Homeostasis and Chronic Lung Diseases.International journal of biological sciences · 2025Review
- PTGES is involved in myofibroblast differentiation via HIF-1α-dependent glycolysis pathway.Journal of cellular and molecular medicine · 2024Article
- Reduced sensitivity to thyroid hormones is associated with lung function in euthyroid individuals.Heliyon · 2024Article
- Association Between Myocardial Infarction and Triglyceride-Glucose Index: A Study Based on NHANES Database.Global heart · 2024Article
- METTL3-mediated m6A RNA methylation induces the differentiation of lung resident mesenchymal stem cells into myofibroblasts via the miR-21/PTEN pathway.Respiratory research · 2023Review
- Monocytes and macrophages: emerging mechanisms and novel therapeutic targets in pulmonary fibrosis.American journal of physiology. Cell physiology · 2023Review
- Exploring Patient Beliefs and Medication Adherence in the Mediterranean Context: A Cross-Sectional Study in Patients with Cardiovascular Diseases and Cardiometabolic Disorders in Greece-The IACT-Study.Life (Basel, Switzerland) · 2023Article
- Fanconi syndrome-associated interstitial lung disease.BMJ case reports · 2022Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic lung diseases represent complex diseases with gradually increasing incidence, characterized by significant medical and financial burden for both patients and relatives. Their increasing incidence and complexity render a comprehensive, multidisciplinary, and personalized approach critically important. This approach includes the assessment of comorbid conditions including metabolic dysfunctions. Several lines of evidence show that metabolic comorbidities, including diabetes mellitus, dyslipidemia, osteoporosis, vitamin D deficiency, and thyroid dysfunction have a significant impact on symptoms, quality of life, management, economic burden, and disease mortality. Most recently, novel pathogenetic pathways and potential therapeutic targets have been identified through large-scale studies of metabolites, called metabolomics. This review article aims to summarize the current state of knowledge on the prevalence of metabolic comorbidities in chronic lung diseases, highlight their impact on disease clinical course, delineate mechanistic links, and report future perspectives on the role of metabolites as disease modifiers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.